Merck to buy Schering-Plough for $41.1 billion
Pharmaceutical giant Merck & Co., Inc on Monday said it will buy rival Schering-Plough for $41.1 billion in cash and shares to expand its presence in emerging markets and bolster its pipeline of potential new medicines.
Drug developer Schering-Plough Corp. spent $520,000 in the first quarter to lobby on patent reform legislation, drug safety and other issues, according to a disclosure report.